eCite Digital Repository

Neuroglial responses to CNS injury: prospects for novel therapeutics


Kilpatrick, TJ and Butzkueven, H and Emery, B and Marriott, M and Taylor, BV and Tubridy, N, Neuroglial responses to CNS injury: prospects for novel therapeutics, Expert Review of Neurotherapeutics, 4, (5) pp. 869-878. ISSN 1744-8360 (2004) [Refereed Article]

DOI: doi:10.1586/14737175.4.5.869


Immune-mediated therapies can reduce the relapse rate in multiple sclerosis. However, there is no clear-cut evidence that any of these therapies substantially alter the long-term outcome for patients with progressive multiple sclerosis. The neurological disability that all too frequently accompanies multiple sclerosis is ultimately due to injury to target cells, principally oligodendroglia, within the nervous system. Recent data suggest that activation of leukemia inhibitory factor-receptor signaling is an important component of a neurobiological response that serves to limit the extent of immune-mediated injury. Therefore, inactivation of this pathway could provide a novel approach to the treatment of demyelinating disease.

Item Details

Item Type:Refereed Article
Research Division:Biomedical and Clinical Sciences
Research Group:Neurosciences
Research Field:Central nervous system
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Taylor, BV (Professor Bruce Taylor)
ID Code:63391
Year Published:2004
Deposited By:Menzies Institute for Medical Research
Deposited On:2010-05-05
Last Modified:2011-10-04

Repository Staff Only: item control page